Epsilon M&A Deal Report - Biotest
Transaction Multiples for the Valuation of Private Companies
Grifols / Biotest
No EMAT :
122311
Announced Date :
17/09/2021
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Grifols
Target :
Biotest
Country :
Germany
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
Business Description :
Biotest is a German biotechnology company founded in 1946, that s pecializes in plasma-derived protein therapeutics for clinical immunology, hematology and intensive care medicine. > R&D, production...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
ns | ns | ns | ns |
|
||
| Current |
|
ns | ns | ns | ns |
Rating :
***
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 133
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 58
| Date | Acquirer | Target | Country | Multiples | See details |
| 02/08/2024 | Private Group led by 21 Invest | Rocamed SAM | Monaco | * | 122117 |
| 07/02/2025 | Private Group led by LBO France | Hemodia | France | ** | 121872 |
Source: Epsilon Research / EMAT
